BridgeBio have demonstrably advanced its development of a new solution for cardiac amyloidosis, utilizing the investigational drug. Preliminary trial data reveals promising benefits for patients diagnosed from the severe illness. This focus highlights BridgeBio's commitment to addressing unmet me